No Data
No Data
Yun Zhong, PhD, Joins Wedbush Securities as Senior Vice President, Equity Research, Biotechnology
Optimistic Buy Rating for Passage Bio Driven by Promising PBFT02 Therapy Potential and Accelerated Approval Pathway
Passage Bio Assumed With an Outperform at Wedbush
12 Health Care Stocks Moving In Friday's Pre-Market Session
Passage Bio Coverage Assumed by Wedbush at Outperform
Passage Bio Price Target Announced at $4.00/Share by Wedbush
No Data
No Data